Abeona Therapeutics ABEO 深 滬
等待開盤 11-04 09:30:00 美东时间
4.25
0.000
0.00%
華盛通- 最 高4.4001
- 今 開4.27
- 成交量 112.33万股
- 最 低 4.20
- 昨 收 4.25
- 總市值 2.43亿
- 52周最高 7.65
- 市盈率 靜 4.19
- 換手率 1.96%
- 52周最低 4.16
- 委 比 52.26%
- 總股本 5718.40万
- 歷史最高 750.00
- 量 比 1.42
- 振 幅 4.71%
- 歷史最低 2.19
- 每 手 1
- 風險率 0.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc. granted equity awards to two new non-executive employees, totaling up to 5,100 restricted shares of common stock. The awards vest annually over three years, contingent on continued employment. Abeona is a commercial-stage biopharmaceutical company focused on cell and gene therapies, with ZEVASKYN® as its lead product for treating recessive dystrophic epidermolysis bullosa.
11-02 12:46
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Cardiff Oncology appoints Leila Alland, MD, as interim Chief Medical Officer, replacing Roger Sidhu, MD. Dr. Alland brings extensive oncology drug development experience, having led programs at多家生物制药公司, including AstraZeneca, Bristol Myers Squibb, and Novartis. Her expertise will guide Cardiff's Phase 3 study for onvansertib, a PLK1 inhibitor targeting RAS-mutated cancers, as the company prepares to initiate its registrational Phase 3 trial in ea...
10-27 20:05
Abeona Therapeutics 13D Filing Shows James Russell Revocable Trust Raises Stake In Co To 6.1% As Of October 15, 2026
Abeona Therapeutics 13D Filing Shows James Russell Revocable Trust Raises Stake In Co To 6.1% As Of October 15, 2026
10-24 02:43
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc. granted restricted stock equity awards to two new non-executive employees, totaling up to 7,200 shares. The shares vest annually over three years, contingent on continued employment. Abeona is a biopharmaceutical company developing cell and gene therapies, including ZEVASKYN® for recessive dystrophic epidermolysis bullosa and ABO-701 for solid tumors.
10-02 11:30
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Deutsche Bank cut the price target for Xenon Pharmaceuticals Inc (NASDAQ:XENE) from $90 to $46. Deutsche Bank ...
09-18 20:31
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.
09-17 18:09
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
Abeona Therapeutics has activated the University of Florida Health (UF Health) as the eighth Qualified Treatment Center (QTC) for administering ZEVASKYN, the first and only autologous gene-modified cellular sheets for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). This expansion aims to increase access to the innovative gene therapy for patients in Florida and the southeastern United States. ZEVASKYN addresses...
09-16 11:30
Abeona Therapeutics Updates Investor Presentation at Conference
Abeona Therapeutics ( ($ABEO) ) has shared an update. Abeona Therapeutics Inc. ...
09-16 00:47
